Peptides›Metabolic›CagriSema

CagriSema

/ Fixed-ratio coformulation: cagrilintide (amylin agonist) plus semaglutide (GLP-1 agonist)

TIER 2 · TranslationalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Fixed-ratio coformulation: cagrilintide (amylin agonist) plus semaglutide (GLP-1 agonist)CATEGORY · Metabolic

Investigational. Phase 3 REDEFINE program topline readouts reported through 2025. Not FDA-approved as of April 2026.

§ B · Mechanism of action

Fixed-ratio coformulation (1:1) of cagrilintide, a long-acting amylin-receptor agonist with activity at AMY1/2/3 receptors (calcitonin-receptor/RAMP heterodimers), plus semaglutide. Amylin agonism complements GLP-1 by enhancing satiety and slowing gastric emptying through a distinct receptor family. The combination is hypothesized to produce additive or synergistic weight effects with a potentially improved tolerability ceiling versus higher single-agent GLP-1 doses.

§ C · Human clinical evidence

Phase 2 in type 2 diabetes (Frias 2023) showed -2.18% HbA1c and -15.6% weight at 32 weeks. Phase 3 REDEFINE 1 reported -22.7% weight change vs -16.1% semaglutide alone over 68 weeks.

§ D · Primary literature

PubMed37356447Frías JP et al. — Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial · Lancet · human-phase-2HbA1c -2.18% and weight -15.6% with CagriSema vs -1.80%/-5.1% with semaglutide alone at 32 weeks in type 2 diabetes.Limitations: Small sample; Phase 2. Phase 3 REDEFINE results published separately (Garvey 2025).2023

§ F · Safety signal

Gastrointestinal profile similar to semaglutide; nausea ~55%, vomiting ~23%, slightly higher than semaglutide alone but comparable to cagrilintide alone in reported trials. No new safety signals emerged in REDEFINE 1.

§ H · Regulatory status

Regulatory status

FDA status:: Investigational (Phase 3)
Compounding:: Not eligible for compounding (approved, not in shortage)

§ I · Notable gaps and controversies

CagriSema is not approved. Cagrilintide is not a pharmacopeial API. Online offerings of "CagriSema" are not legitimate research material sourced from established API manufacturers.